References
- Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974;54:271-6.
- Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease: a 10- to 21-year follow-up study of 594 patients. Circulation 1996;94:1379-85. https://doi.org/10.1161/01.CIR.94.6.1379
- Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315:341-7. https://doi.org/10.1056/NEJM198608073150601
- Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-9. https://doi.org/10.1056/NEJM199106063242305
- Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J 1998;17:1144-8. https://doi.org/10.1097/00006454-199812000-00009
- Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 2003;24:145-8. https://doi.org/10.1007/s00246-002-0216-2
- Lang BA, Yeung RS, Oen KG, et al. Corticosteroid treatment of refractory Kawasaki disease. J Rheumatol 2006;33:803-9.
- Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005;146:662-7. https://doi.org/10.1016/j.jpeds.2004.12.022
- Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004;110:2747-71. https://doi.org/10.1161/01.CIR.0000145143.19711.78
- Weiss JE, Eberhard A, Chowdhury D, Gottlieb BS. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004;31: 808-10.
- Research Committee on Kawasaki Disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Tokyo, Japan: Ministry of Health and Welfare; 1984.
- Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW. Gamma globulin re-treatment in Kawasaki disease. J Pediatr 1993;123:657-9. https://doi.org/10.1016/S0022-3476(05)80972-2
- Burns JC, Glode MP. Kawasaki syndrome. Lancet 2004;364:533-44. https://doi.org/10.1016/S0140-6736(04)16814-1
- Freeman AF, Shulman ST. Refractory Kawasaki disease. Pediatr Infect Dis J 2004;23:463-4. https://doi.org/10.1097/01.inf.0000125893.66941.e0
- Nachiappan J, May M, Hawker RE, Hong P. Resistant Kawasaki disease. J Paediatr Child Health 2004;40:576-8. https://doi.org/10.1111/j.1440-1754.2004.00467.x
- Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113:2606-12. https://doi.org/10.1161/CIRCULATIONAHA.105.592865
- Fukunishi M, Kikkawa M, Hamana K, et al. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000;137:172-6. https://doi.org/10.1067/mpd.2000.104815
- Muta H, Ishii M, Egami K, et al. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. J Pediatr 2004;144:496-9. https://doi.org/10.1016/j.jpeds.2003.12.033
- Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979;63:175-9.
- Wright DA, Newburger JW, Baker A, Sumdel RP. Treatment of immune- globulin resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996;128:146-9. https://doi.org/10.1016/S0022-3476(96)70447-X
- Miura M, Ohki H, Yoshiba S, et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch Dis Child 2005;90:1096-7. https://doi.org/10.1136/adc.2004.062299
- Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child 2008;93:142-6. https://doi.org/10.1136/adc.2007.126144
- Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003;62:245-7. https://doi.org/10.1136/ard.62.3.245
- Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003;98:833-8. https://doi.org/10.1111/j.1572-0241.2003.07343.x
- Hirono K, Kemmotsu Y, Wittkowski H, et al. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr Res 2009;65:696-701. https://doi.org/10.1203/PDR.0b013e31819ed68d
- Hui-Yuen JS, Duong TT, Yeung RS. TNF-alpha is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease. J Immunol 2006;176:6294-301.
- Shin JU, Cho HK, Shin MS. Elevated tumor necrosis factor-alpha in stable angina pectoris. Korean Circ J 2000;30:861-6.
- Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003;17:75-84.
- Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104. https://doi.org/10.1056/NEJMoa011110
- Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7. https://doi.org/10.1097/MPG.0b013e31802f6424
Cited by
- Recent advances in the treatment of Kawasaki disease vol.74, pp.11, 2011, https://doi.org/10.1016/j.jcma.2011.09.001
- Increased Percentages of Tumor Necrosis Factor-α+/Interferon-T+Lymphocytes and Calprotectin+/Tumor Necrosis Factor-A+ Monocytes in Patients with Acute Kawasaki Disease vol.25, pp.1, 2010, https://doi.org/10.1177/039463201202500112
- The Clinical Diagnosis and Management of Kawasaki Disease: a Review and Update vol.18, pp.10, 2016, https://doi.org/10.1007/s11908-016-0538-5
- Infliximab for Intravenous Immunoglobulin-Resistant Patients with Kawasaki Disease: A Single-Institute Study vol.33, pp.1, 2017, https://doi.org/10.9794/jspccs.33.43
- Analysis of biomarker serum levels in IVIG and infliximab refractory Kawasaki disease patients vol.37, pp.7, 2010, https://doi.org/10.1007/s10067-017-3952-7
- Examining maintenance care following infliximab salvage therapy for acute severe ulcerative colitis vol.33, pp.1, 2018, https://doi.org/10.1111/jgh.13850
- Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm vol.19, pp.2, 2010, https://doi.org/10.1007/s10238-018-00544-5
- A Cost Comparison of Infliximab Versus Intravenous Immunoglobulin for Refractory Kawasaki Disease Treatment vol.11, pp.1, 2010, https://doi.org/10.1542/hpeds.2020-0188
- Clinical profile, treatment and outcome of Kawasaki disease: A single‐center experience from a tertiary care referral center of Assam, north‐east India vol.24, pp.3, 2021, https://doi.org/10.1111/1756-185x.14059